SecBot SecBot
PRESS-RELEASE ·Filed Aug 27, 2026

LFVN

LifeVantage Corporation
BEARISH
Impact 7/10
Horizonweeks Processed2mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

With FY2027 guidance withdrawn and a new CEO just starting, the near-term outlook is highly uncertain. Monitor for the new CEO's strategic update and any signs of stabilization in active account trends. The debt-free balance sheet provides a cushion, but the 23% revenue decline and 21% account erosion suggest a fundamental business contraction that will require a credible turnaround plan to reverse.

DirectionBearish
Confidencehigh
Horizonweeks
Latest settled — T+20d
LFVN ▼ -2.60% at T+20d
SHORT call ✓ call won +2.60% · α vs SPY +2.86% · entry $6.36 → $6.19
Next anchor: T+60d in 23d
Latest observation: T+40 -29.30% FF3 residual α
Entry = T+0 close
Aug 27, 2026
via day close
T+1d
-0.39%
call +0.39% · α +0.09%
$6.33
settled 2mo ago
T+5d
-1.65%
call +1.65% · α +1.76%
$6.25
settled 8w ago
T+20d
-2.60%
call +2.60% · α +2.86%
$6.19
settled 5w ago
T+60d
Pending
in 23d

Price Chart

Loading chart...

Executive Summary

LifeVantage reported Q4 FY2026 revenue of $42.4M (down 23.1% YoY) and GAAP EPS of $0.10 (down from $0.15 YoY), missing consensus estimates of $0.13 EPS on $44.0M revenue. The company withdrew FY2027 guidance due to a CEO transition, adding uncertainty. Revenue declines were broad-based across regions and product lines, with active accounts down 21.2% YoY.

Key Financial Metrics

EPS
$0.10
est $0.13 · -23.1%
Revenue
$42.4M
est $44.0M · -3.7% · -23.1% YoY
Rating
miss
Gross Margin
78%

Key Facts

  • Q4 FY2026 revenue $42.4M, down 23.1% YoY from $55.1M
  • GAAP EPS $0.10 vs $0.15 YoY; adjusted EPS $0.11 vs $0.17 YoY
  • EPS missed consensus of $0.13; revenue missed $44.0M consensus
  • Full-year FY2026 revenue $182.6M, down 20.1% YoY
  • Active accounts declined 21.2% YoY to 104,000
  • FY2027 guidance withdrawn due to CEO transition
  • Cash and equivalents $14.9M, down from $20.2M; no debt
  • $58.5M remaining under share repurchase program

Financial Impact

Revenue decline of $12.7M (-23.1%) YoY in Q4; EPS decline of $0.05 (-33%) YoY; full-year revenue decline of $45.9M (-20.1%)

revenueepsactive accountsgross margin

Risk Factors

  • Continued revenue decline without guidance to anchor expectations
  • CEO transition may delay strategic initiatives and recovery
  • Active account base erosion accelerating (down 21.2% YoY)
  • GLP-1 System inventory obsolescence ($2.5M charge) signals product lifecycle challenges
  • Cash burn: $5.3M decline in cash from FY2025 to FY2026

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3352394
5 reports for LFVN
Performance horizon
Filters
Rows
Reports for LFVN — sortable, filterable
TypeNow
Oct 22, 2026
5d ago
SC 13G/A
NEUTRAL ★ 3/10
$5.86awaiting T+20—$5.93 (+1.19%)
Aug 27, 2026
8w ago
Press Release
BEARISH ★ 7/10
$6.36 $6.19▲ +2.60%▲ +2.86%$5.93 (+6.69%)
Aug 21, 2026
9w ago
Press Release
NEUTRAL ★ 2/10
$6.69 $6.22▼ −7.03%▼ −6.50%$5.93 (−11.36%)
Apr 22, 2026
26w ago
Press Release
NEUTRAL ★ 1/10
$4.96 $5.25▲ +5.85%▲ +1.21%$5.93 (+19.56%)
Mar 23, 2026
31w ago
EFFECT
NEUTRAL ★ 4/10
$4.54 $4.91▲ +8.15%▲ +0.73%$5.93 (+30.62%)
Showing 5 of 5

US Market Status

Market Closed — Opens in 9h 26m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 27, 2026